Familial hypercholesterolemia patients treated with statins at no increased risk for intracranial vascular lesions despite increased cholesterol burden and extracranial atherosclerosis

Stroke. 2005 Jul;36(7):1572-4. doi: 10.1161/01.STR.0000169920.64180.fa. Epub 2005 Jun 2.

Abstract

Background and purpose: To correlate known vascular disease risk factors and the signs of extracranial and intracranial changes of vascular origin in young patients with heterozygous familial hypercholesterolemia (FH).

Methods: 39 DNA test-verified heterozygous FH North Karelian patients (FH-NK), aged 6 to 48, 28 of them treated with statins, and 25 healthy controls underwent brain magnetic resonance imaging (MRI) and carotid ultrasound.

Results: Common carotid intima-media thickness was significantly greater in the patients (P=0.005). MR angiography showed no pathological changes, other than 1 incidental aneurysm. The number and size of white matter hyperintensities on T2-weighted MR images, considered as markers of microvascular alterations, did not differ between patients and controls.

Conclusions: FH-NK patients treated with statins seem to be at no increased risk for brain infarcts or other brain lesions of vascular origin when younger than age 50.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Arteriosclerosis / pathology
  • Atherosclerosis / complications*
  • Blood Pressure
  • Brain Infarction / diagnosis*
  • Brain Infarction / pathology
  • Case-Control Studies
  • Cerebrovascular Circulation
  • Child
  • Cholesterol / metabolism*
  • Heterozygote
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / pathology
  • Hyperlipoproteinemia Type II / drug therapy*
  • Hyperlipoproteinemia Type II / genetics*
  • Hyperlipoproteinemia Type II / pathology*
  • Magnetic Resonance Imaging
  • Middle Aged
  • Risk
  • Risk Factors
  • Tunica Intima / pathology
  • Tunica Media / pathology
  • Ultrasonography

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Cholesterol